How I treat relapsed multiple myeloma
Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of sever...
Saved in:
| Published in: | Blood Vol. 139; no. 19; p. 2904 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
12.05.2022
|
| Subjects: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of several new agents, myeloma treatment has changed drastically, and there are new options for the management of relapsed or refractory disease, including new drug classes with distinct mechanisms of action and cellular therapies. However, resistance to major drug classes used in first-line remains the most critical factor for the choice of treatment at relapse. Continuous lenalidomide-based therapy is used extensively at first-line, and resistance to lenalidomide has become the key factor for the choice of salvage therapy. Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge. Three-drug regimens are the standard approach to manage relapsed disease. Adding drugs with new mechanisms of activity can improve outcomes and overcomes class resistance, but, until now, while biology is important, it can offer only limited guidance for the choice of therapy. |
|---|---|
| AbstractList | Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of several new agents, myeloma treatment has changed drastically, and there are new options for the management of relapsed or refractory disease, including new drug classes with distinct mechanisms of action and cellular therapies. However, resistance to major drug classes used in first-line remains the most critical factor for the choice of treatment at relapse. Continuous lenalidomide-based therapy is used extensively at first-line, and resistance to lenalidomide has become the key factor for the choice of salvage therapy. Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge. Three-drug regimens are the standard approach to manage relapsed disease. Adding drugs with new mechanisms of activity can improve outcomes and overcomes class resistance, but, until now, while biology is important, it can offer only limited guidance for the choice of therapy. Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of several new agents, myeloma treatment has changed drastically, and there are new options for the management of relapsed or refractory disease, including new drug classes with distinct mechanisms of action and cellular therapies. However, resistance to major drug classes used in first-line remains the most critical factor for the choice of treatment at relapse. Continuous lenalidomide-based therapy is used extensively at first-line, and resistance to lenalidomide has become the key factor for the choice of salvage therapy. Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge. Three-drug regimens are the standard approach to manage relapsed disease. Adding drugs with new mechanisms of activity can improve outcomes and overcomes class resistance, but, until now, while biology is important, it can offer only limited guidance for the choice of therapy.Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of several new agents, myeloma treatment has changed drastically, and there are new options for the management of relapsed or refractory disease, including new drug classes with distinct mechanisms of action and cellular therapies. However, resistance to major drug classes used in first-line remains the most critical factor for the choice of treatment at relapse. Continuous lenalidomide-based therapy is used extensively at first-line, and resistance to lenalidomide has become the key factor for the choice of salvage therapy. Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge. Three-drug regimens are the standard approach to manage relapsed disease. Adding drugs with new mechanisms of activity can improve outcomes and overcomes class resistance, but, until now, while biology is important, it can offer only limited guidance for the choice of therapy. |
| Author | Dimopoulos, Meletios A Terpos, Evangelos Kastritis, Efstathios |
| Author_xml | – sequence: 1 givenname: Efstathios orcidid: 0000-0001-8191-5832 surname: Kastritis fullname: Kastritis, Efstathios organization: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece – sequence: 2 givenname: Evangelos orcidid: 0000-0001-5133-1422 surname: Terpos fullname: Terpos, Evangelos organization: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece – sequence: 3 givenname: Meletios A orcidid: 0000-0001-8990-3254 surname: Dimopoulos fullname: Dimopoulos, Meletios A organization: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35007326$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj01Lw0AURQep2A_du5JsBDep773JTKdLKWoLBTe6DpPJG4hMOjGTIP33Fqzg6l4Ohwt3LiaHeGAhbhGWiIYeqxBjvSQgADArWVyIGSoyOZzI5F-finlKnwBYSFJXYioVwEqSnon7bfzOdtnQsx2ynoPtEtdZO4ah6QJn7ZFDbO21uPQ2JL4550J8vDy_b7b5_u11t3na504SDbknqNaotXZy5VEzK8nKkgVjEGvE6oRcgaAkODRSW6OMdoa89N5V6GkhHn53uz5-jZyGsm2S4xDsgeOYStJozNroAk_q3Vkdq5brsuub1vbH8u8a_QA4PVCt |
| CitedBy_id | crossref_primary_10_1002_hem3_110 crossref_primary_10_3390_cancers15082203 crossref_primary_10_1039_D3BM00470H crossref_primary_10_1200_GO_23_00182 crossref_primary_10_3389_fonc_2022_890376 crossref_primary_10_1038_s41467_024_51442_2 crossref_primary_10_1002_hem3_81 crossref_primary_10_3324_haematol_2024_285002 crossref_primary_10_3390_biom12111647 crossref_primary_10_1007_s00432_023_05385_8 crossref_primary_10_1007_s10238_025_01692_1 crossref_primary_10_1038_s41420_024_02239_1 crossref_primary_10_1053_j_seminoncol_2022_01_011 crossref_primary_10_3390_cancers17071168 crossref_primary_10_1038_s41598_024_66367_5 crossref_primary_10_1016_j_clml_2024_09_008 crossref_primary_10_1080_14737159_2024_2399152 crossref_primary_10_1007_s40273_024_01399_3 crossref_primary_10_1182_bloodadvances_2022008241 crossref_primary_10_1016_S2152_2650_24_00361_6 crossref_primary_10_1021_acschembio_5c00270 crossref_primary_10_1093_carcin_bgac097 crossref_primary_10_1016_j_phymed_2025_157168 crossref_primary_10_1016_j_canlet_2022_216019 crossref_primary_10_3390_molecules28031456 crossref_primary_10_1016_j_retram_2025_103495 crossref_primary_10_1111_ejh_14266 crossref_primary_10_1016_j_clml_2025_07_007 crossref_primary_10_1080_16078454_2024_2335421 crossref_primary_10_1038_s41467_024_44873_4 crossref_primary_10_1007_s12026_024_09546_w crossref_primary_10_1016_j_mayocp_2025_05_009 crossref_primary_10_1038_s41401_025_01553_3 |
| ContentType | Journal Article |
| Copyright | 2022 by The American Society of Hematology. |
| Copyright_xml | – notice: 2022 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood.2020008734 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 35007326 |
| Genre | Journal Article |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AFETI AFOSN AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 |
| ID | FETCH-LOGICAL-c322t-f20b91666c37f16ee53e5a2a08811d11b6eec410530c1836a8586c82f3ffcb1f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 38 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000805829900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Thu Oct 02 10:50:25 EDT 2025 Mon Jul 21 06:00:56 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Language | English |
| License | 2022 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c322t-f20b91666c37f16ee53e5a2a08811d11b6eec410530c1836a8586c82f3ffcb1f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-5133-1422 0000-0001-8191-5832 0000-0001-8990-3254 |
| OpenAccessLink | https://ashpublications.org/blood/article-pdf/139/19/2904/1896526/bloodbld2020008734c.pdf |
| PMID | 35007326 |
| PQID | 2618898641 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2618898641 pubmed_primary_35007326 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-May-12 20220512 |
| PublicationDateYYYYMMDD | 2022-05-12 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-May-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2022 |
| SSID | ssj0014325 |
| Score | 2.5454218 |
| Snippet | Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2904 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Humans Lenalidomide - therapeutic use Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - drug therapy Salvage Therapy |
| Title | How I treat relapsed multiple myeloma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35007326 https://www.proquest.com/docview/2618898641 |
| Volume | 139 |
| WOSCitedRecordID | wos000805829900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7U-rr4aH3UFyuot6XdbJNsTlKLpYItPaj0VjabXRBsUk1V-u_d2Sb0JAheQggEktmdx873zQzAlS89Zd1Oi_oyjmkrkpoKbTQ1ggvNlI0pXE735TEcDMRoFA2LhFte0CpLm-gMdZIpzJE3bKQvBPYSZ7fTd4pToxBdLUZorEKF21AGKV3haIkitLgbumpdlKAYF5UwpfAajhZuj4dYqSJCHJv8W4DpHE1397-fuAc7RYhJ2os9sQ8rOq1CrZ3a4_VkTm6II326bHoVNu7Ku61OOfqtCpv9AnGvwXUv-yYPxPHRCRa-THOdkJKGSCZz_ZZN5AE8d--fOj1ajFagymrwjBqvGUeIGCoeGhZo7XNtl01am8NYwlhsHylkgPKmskofSOGLQAnPcGNUzIx3CGtplupjINhBLkE8k8USQbjY-MYuBuOBafoyCupwWUprbH8D8QiZ6uwzHy_lVYejhcjH00WPjTH3EUP0gpM_vH0K2x4WJWBPVe8MKsYqrj6HdfU1e80_LtyesNfBsP8DNLi9tw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=How+I+treat+relapsed+multiple+myeloma&rft.jtitle=Blood&rft.au=Kastritis%2C+Efstathios&rft.au=Terpos%2C+Evangelos&rft.au=Dimopoulos%2C+Meletios+A&rft.date=2022-05-12&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=139&rft.issue=19&rft.spage=2904&rft_id=info:doi/10.1182%2Fblood.2020008734&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |